Transient Pharma AB is a privately held unlisted public company with headquarter in Lund, Sweden. Our mission is to develop innovative treatments for diseases characterized by disproportional activation of inflammation, leveraging the body’s natural defense system as a template. Our technology is based on 15+ years of research on Thrombin-derived C-terminal peptides (TCPs) by Professor Artur Schmidtchen and his team. Transient Pharma specializes in the development of proprietary peptide-based drugs based on TCPs for prevention and treatment of serious inflammatory conditions.

Inflammation is the body’s natural response to injury and infection. However when inflammation becomes unbalanced or chronic it poses a major threat to human health leading to significant mortality and substantial costs to society. Professor Artur Schmidtchen, founder of the company, has together with his team demonstrated that Thrombin-derived C-terminal peptides (TCPs) are released after proteolytic cleavage of thrombin as a natural response to injury and infection. These peptides exhibit both anti-inflammatory and anti-microbial activity. Transient Pharma’s novel drug candidate is designed with the targeted structure of TCPs, harnessing their unique mechanism of action, but is more stable and suitable for systemic use in treating serious inflammatory diseases.

Our ambition is to demonstrate the clinical utility of our first drug candidate, TIM-03, as a novel treatment for inflammatory diseases. TIM-03´s unique mode of action makes it a promising drug candidate for a wide range of diseases with a high unmet medical need, where disproportional inflammation is the main cause. Our primary goal is to take the development to proof-of-concept in a clinical study, either independently or in collaboration with a partner. Strategically, further development leading to world-wide registration of a new medicine, and subsequent efforts to make the medicine accessible to patients will likely involve partnership or out-licensing of the technology.